Skip to Main Content
Welcome to the Marketplace

Go to Main Navigation

32-13840-0 32-13840

HIV-2 gp160



Source:Escherichia Coli.Physical Appearance:Sterile Filtered clear solution.Biological ActivitynullHIV-1 & HIV-2 appear to package their RNA differently. HIV-1 binds to any appropriate RNA whereas HIV-2 preferentially binds to mRNA which creates the Gag protein itself. This means that HIV-1 is better able to mutate. HIV-2 is transmitted in the same ways as HIV-1: Through exposure to bodily fluids such as blood, semen, tears & vaginal fluids. Immunodeficiency develops more slowly with HIV-2. HIV-2 is less infectious in the early stages of the virus than with HIV-1. The infectiousness of HIV-2 increases as the virus progresses. Major differences include reduced pathogenicity of HIV-2 relative to HIV-1, enhanced immune control of HIV-2 infection & often some degree of CD4-independence. Despite considerable sequence & phenotypic differences between HIV-1 & 2 envelopes, structurally they are quite similar. Both membrane-anchored proteins eventually form the 6-helix bundles from the N-terminal & C-terminal regions of the ectodomain, which is common to many viral & cellular fusion proteins & which seems to drive fusion. HIV2 gp160 protein contains HIV2 Subtype A sequence, covering C4, V5, & C5 from HIV2 gp120 & extending to HIV2 gp36.HIV-2 gp160 produced in E. coli having a Mw of 41kDa.


  • Format Id: HIV-2 gp160 solution contains 0.025% NaN3, 25mM Tris-Base & 25mM K2CO3.
  • Purification: Protein is >95% pure as determined by 10% PAGE (coomassie staining).
  • Storage Condition: Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Avoid multiple freeze-thaw cycles.